Acute myeloid leukemia targeting by myxoma virus in vivo depends on cell binding but not permissiveness to infection in vitro

Cited 19 time in scopus
Metadata Downloads

Full metadata record

DC FieldValueLanguage
dc.contributor.authorG J Madlambayan-
dc.contributor.authorE Bartee-
dc.contributor.authorMan Bok Kim-
dc.contributor.authorM M Rahman-
dc.contributor.authorA Meacham-
dc.contributor.authorE W Scott-
dc.contributor.authorG McFadden-
dc.contributor.authorC R Cogle-
dc.date.accessioned2017-04-19T09:32:08Z-
dc.date.available2017-04-19T09:32:08Z-
dc.date.issued2012-
dc.identifier.issn0145-2126-
dc.identifier.uri10.1016/j.leukres.2012.01.020ko
dc.identifier.urihttps://oak.kribb.re.kr/handle/201005/10793-
dc.description.abstractSome oncolytic viruses, such as myxoma virus (MYXV), can selectively target malignant hematopoietic cells, while sparing normal hematopoietic cells. This capacity for discrimination creates an opportunity to use oncolytic viruses as ex vivo purging agents of autologous hematopoietic cell grafts in patients with hematologic malignancies. However, the mechanisms by which oncolytic viruses select malignant hematopoietic cells are poorly understood. In this study, we investigated how MYXV specifically targets human AML cells. MYXV prevented chloroma formation and bone marrow engraftment of two human AML cell lines, KG-1 and THP-1. The reduction in human leukemia engraftment after ex vivo MYXV treatment was dose-dependent and required a minimum MOI of 3. Both AML cell lines demonstrated MYXV binding to leukemia cell membranes following co-incubation: however, evidence of productive MYXV infection was observed only in THP-1 cells. This observation, that KG-1 can be targeted in vivo even in the absence of in vitro permissive viral infection, contrasts with the current understanding of oncolytic virotherapy, which assumes that virus infection and productive replication is a requirement. Preventing MYXV binding to AML cells with heparin abrogated the purging capacity of MYXV, indicating that binding of infectious virus particles is a necessary step for effective viral oncolysis. Our results challenge the current dogma of oncolytic virotherapy and show that in vitro permissiveness to an oncolytic virus is not necessarily an accurate predictor of oncolytic potency in vivo.-
dc.publisherElsevier-
dc.titleAcute myeloid leukemia targeting by myxoma virus in vivo depends on cell binding but not permissiveness to infection in vitro-
dc.title.alternativeAcute myeloid leukemia targeting by myxoma virus in vivo depends on cell binding but not permissiveness to infection in vitro-
dc.typeArticle-
dc.citation.titleLeukemia Research-
dc.citation.number5-
dc.citation.endPage624-
dc.citation.startPage619-
dc.citation.volume36-
dc.contributor.affiliatedAuthorMan Bok Kim-
dc.contributor.alternativeNameMadlambayan-
dc.contributor.alternativeNameBartee-
dc.contributor.alternativeName김만복-
dc.contributor.alternativeNameRahman-
dc.contributor.alternativeNameMeacham-
dc.contributor.alternativeNameScott-
dc.contributor.alternativeNameMcFadden-
dc.contributor.alternativeNameCogle-
dc.identifier.bibliographicCitationLeukemia Research, vol. 36, no. 5, pp. 619-624-
dc.identifier.doi10.1016/j.leukres.2012.01.020-
dc.subject.keywordAnimal models-
dc.subject.keywordBone marrow-
dc.subject.keywordHematopoietic stem cell-
dc.subject.keywordLeukemia-
dc.subject.keywordOncolytic virotherapy-
dc.subject.localAnimal model-
dc.subject.localAnimal models-
dc.subject.localanimal models-
dc.subject.localAnimal Model-
dc.subject.localanimal model-
dc.subject.localAnimal Models-
dc.subject.localBone marrow-
dc.subject.localHematopoietic stem cell-
dc.subject.localhematopoietic stem cell-
dc.subject.localHematopoietic stem cells-
dc.subject.localleukemia-
dc.subject.localLeukemia-
dc.subject.localLeukemias-
dc.subject.localOncolytic virotherapy-
dc.description.journalClassY-
Appears in Collections:
1. Journal Articles > Journal Articles
Files in This Item:
  • There are no files associated with this item.


Items in OpenAccess@KRIBB are protected by copyright, with all rights reserved, unless otherwise indicated.